Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Authors:
- 13 September 2022
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (12) , 1703-1715
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War
- Biomedical Advanced Research and Development Authority (HHSO100201700018C)
- National Institutes of Health (COV3009)
This publication has 22 references indexed in Scilit:
- SARS-CoV-2 vaccine protection and deaths among US veterans during 2021Science, 2022
- Covid-19 Vaccine Effectiveness in New York StateNew England Journal of Medicine, 2021
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistanceJournal of Microbiology, 2021
- SARS-CoV-2 Variants and VaccinesNew England Journal of Medicine, 2021
- Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19Cell Reports, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 VaccineNew England Journal of Medicine, 2021
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesnpj Vaccines, 2020